RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Clinical trials for RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM trials appear
Sign up with your email to follow new studies for RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Matched conditions: RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
New hope for kids with tough cancers: targeted drug shows promise in early trial
Disease control CompletedThis study tested a drug called samotolisib in 18 children and teens whose cancers (solid tumors, lymphoma, or related disorders) had spread, returned, or stopped responding to treatment. Only those with specific gene mutations (TSC or PI3K/MTOR) were eligible. The goal was to se…
Matched conditions: RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:02 UTC